1
|
Geoghegan JG and Scheele J: Treatment of
colorectal liver metastases. Br J Surg. 86:158–169. 1999.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Yokota J: Tumor progression and
metastasis. Carcinogenesis. 21:497–503. 2000. View Article : Google Scholar : PubMed/NCBI
|
3
|
Fidler IJ: The pathogenesis of cancer
metastasis: The 'seed and soil' hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Lund AH and van Lohuizen M: RUNX: A
trilogy of cancer genes. Cancer Cell. 1:213–215. 2002. View Article : Google Scholar : PubMed/NCBI
|
5
|
Bae SC and Choi JK: Tumor suppressor
activity of RUNX3. Oncogene. 23:4336–4340. 2004. View Article : Google Scholar : PubMed/NCBI
|
6
|
Subramaniam MM, Chan JY, Yeoh KG, Quek T,
Ito K and Salto-Tellez M: Molecular pathology of RUNX3 in human
carcinogenesis. Biochim Biophys Acta. 1796:315–331. 2009.PubMed/NCBI
|
7
|
Li QL, Ito K, Sakakura C, Fukamachi H,
Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, et al: Causal
relationship between the loss of RUNX3 expression and gastric
cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
8
|
Soong R, Shah N, Peh BK, Chong PY, Ng SS,
Zeps N, Joseph D, Salto-Tellez M, Iacopetta B and Ito Y: The
expression of RUNX3 in colorectal cancer is associated with disease
stage and patient outcome. Br J Cancer. 100:676–679. 2009.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Silva TD, Vidigal VM, Felipe AV, DE Lima
JM, Neto RA, Saad SS and Forones NM: DNA methylation as an
epigenetic biomarker in colorectal cancer. Oncol Lett. 6:1687–1692.
2013.PubMed/NCBI
|
10
|
Mu WP, Wang J, Niu Q, Shi N and Lian HF:
Clinical significance and association of RUNX3 hypermethylation
frequency with colorectal cancer: A meta-analysis. Onco Targets
Ther. 7:1237–1245. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Bedi S, Vidyasagar A and Djamali A:
Epithelial-to-mesenchymal transition and chronic allograft
tubulointerstitial fibrosis. Transplant Rev. 22:1–5. 2008.
View Article : Google Scholar
|
13
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Wagenaar-Miller RA, Gorden L and Matrisian
LM: Matrix metalloproteinases in colorectal cancer: Is it worth
talking about? Cancer Metastasis Rev. 23:119–135. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zucker S and Vacirca J: Role of matrix
metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis
Rev. 23:101–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zetter BR: Angiogenesis and tumor
metastasis. Annu Rev Med. 49:407–424. 1998. View Article : Google Scholar : PubMed/NCBI
|
17
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29(Suppl 16): S15–S18. 2002.
View Article : Google Scholar
|
18
|
Leung DW, Cachianes G, Kuang WJ, Goeddel
DV and Ferrara N: Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
|
19
|
Chen F, Bai J, Li W, Mei P, Liu H, Li L,
Pan Z, Wu Y and Zheng J: RUNX3 suppresses migration, invasion and
angiogenesis of human renal cell carcinoma. PLoS One. 8:e562412013.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Chen F, Wang M, Bai J, Liu Q, Xi Y, Li W
and Zheng J: Role of RUNX3 in suppressing metastasis and
angiogenesis of human prostate cancer. PLoS One. 9:e869172014.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Cheng HC, Liu YP, Shan YS, Huang CY, Lin
FC, Lin LC, Lee L, Tsai CH, Hsiao M and Lu PJ: Loss of RUNX3
increases osteopontin expression and promotes cell migration in
gastric cancer. Carcinogenesis. 34:2452–2459. 2013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Tong DD, Jiang Y, Li M, Kong D, Meng XN,
Zhao YZ, Jin Y, Bai J, Fu SB and Geng JS: RUNX3 inhibits cell
proliferation and induces apoptosis by TGF-beta-dependent and
-independent mechanisms in human colon carcinoma cells.
Pathobiology. 76:163–169. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Nishio M, Sakakura C, Nagata T, Komiyama
S, Miyashita A, Hamada T, Kuryu Y, Ikoma H, Kubota T, Kimura A, et
al: RUNX3 promoter methylation in colorectal cancer: Its
relationship with microsatellite instability and its suitability as
a novel serum tumor marker. Anticancer Res. 30:2673–2682.
2010.PubMed/NCBI
|
24
|
Tam WL and Weinberg RA: The epigenetics of
epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449.
2013. View
Article : Google Scholar : PubMed/NCBI
|
25
|
Wang M, Zhao F, Li S, Chang AK, Jia Z,
Chen Y, Xu F, Pan H and Wu H: AIB1 cooperates with ERα to promote
epithelial mesenchymal transition in breast cancer through SNAI1
activation. PLoS One. 8:e655562013. View Article : Google Scholar
|
26
|
Rundhaug JE: Matrix metalloproteinases and
angiogenesis. J Cell Mol Med. 9:267–285. 2005. View Article : Google Scholar : PubMed/NCBI
|
27
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
28
|
Yang B, Tang F, Zhang B, Zhao Y, Feng J
and Rao Z: Matrix metalloproteinase-9 overexpression is closely
related to poor prognosis in patients with colon cancer. World J
Surg Oncol. 12:242014. View Article : Google Scholar : PubMed/NCBI
|
29
|
Cao Y, e G, Wang E, Pal K, Dutta SK,
Bar-Sagi D and Mukhopadhyay D: VEGF exerts an
angiogenesis-independent function in cancer cells to promote their
malignant progression. Cancer Res. 72:3912–3918. 2012. View Article : Google Scholar : PubMed/NCBI
|
30
|
Peng Z, Wei D, Wang L, Tang H, Zhang J, Le
X, Jia Z, Li Q and Xie K: RUNX3 inhibits the expression of vascular
endothelial growth factor and reduces the angiogenesis, growth, and
metastasis of human gastric cancer. Clin Cancer Res. 12:6386–6394.
2006. View Article : Google Scholar : PubMed/NCBI
|